MEDI9929

DRUG3 trials

Sponsors

AstraZeneca, MedImmune LLC, Celeste Porsbjerg

Conditions

AsthmaAtopic DermatitisHealthy

Phase 1

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects

CompletedNCT01913028

AstraZenecaHealthy

Start: 2013-08-31End: 2014-01-31Updated: 2014-02-12

Phase 2

Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis

CompletedNCT02525094

MedImmune LLCAtopic Dermatitis

Start: 2015-08-15End: 2016-07-15Updated: 2018-02-15

Effects of Anti-TSLP in Patients With Asthma

CompletedNCT02698501

Celeste PorsbjergAsthma

Start: 2016-08-31End: 2019-10-07Updated: 2021-06-02

Related Papers

Late Breaking Abstract - Effects of tezepelumab on host epithelial tolerance to virus in patients with uncontrolled asthma

2021-09-055 citations

Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?

2020-10-1535 citations

Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial.

2018-12-12236 citations